Company intelligence / Profile preview
Skyhawk Therapeutics
Boston, Massachusetts, United Statesskyhawktx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
SKYHAWK's lead asset, SKY‑0515 for Huntington’s Disease, demonstrated a dose-dependent reduction of HTT mRNA by up to 72% in healthy volunteers during its Phase 1 multiple ascending dose study and was generally well tolerated. Patient dosing expected Q3 2024 and Phase 2 initiation planned early next year. Additional neurology programs are preclinical.
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- Small molecules (specifically RNA-targeting small molecules)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Genentech/Roche (multi-target deal in oncology/neurodegeneration)Sanofi ($2B+ potential value partnership on splicing modulators)Ipsen ($1.8B alliance focused on rare neurological diseases)Merck/MSD (neurological/cancer collaboration)Vertex Pharmaceuticals
Beyond the preview
Go deeper on Skyhawk Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skyhawk Therapeutics.